Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Zoetis stock in Canada | $201.01

Own Zoetis shares in just a few minutes.

Zoetis Inc
NYSE: ZTS - USD
DRUG MANUFACTURERS-SPECIALTY & GENERIC
$201.79
+ $0.78 ( + 0.39%)

Zoetis is a drug manufacturers-specialty & generic business based in the US. Zoetis stocks (ZTS.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $201.01 – a decrease of 1.45% over the previous week. Zoetis employs 11,300 staff and has a trailing 12-month revenue of around $7.4 billion.

How to buy Zoetis stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ZTS in this case.
  5. Research Zoetis stocks. The platform should provide the latest information available.
  6. Buy your Zoetis stocks. It's that simple.

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Zoetis's stock price?

Since the stock market crash in March caused by coronavirus, Zoetis's stock price has had significant positive movement.

Its last market close was $201.01, which is 29.24% up on its pre-crash value of $142.23 and 123.00% up on the lowest point reached during the March crash when the stocks fell as low as $90.14.

If you had bought $1,000 worth of Zoetis stocks at the start of February 2020, those stocks would have been worth $683.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,483.45.

Zoetis stock price

Use our graph to track the performance of ZTS stocks over time.

Zoetis stocks at a glance

Information last updated 2021-09-18.
Latest market close$201.01
52-week range$141.0212 - $210.1
50-day moving average $204.4059
200-day moving average $181.5524
Wall St. target price$225
PE ratio 49.7593
Dividend yield $0.9 (0.44%)
Earnings per share (TTM) $3.989

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Zoetis price performance over time

Historical closes compared with the last close of $201.01

1 week (2021-09-15) -1.45%
1 month (2021-08-20) -2.92%
3 months (2021-06-22) 7.71%
6 months (2021-03-22) 29.16%
1 year (2020-09-22) 24.46%
2 years (2019-09-20) 60.01%
3 years (2018-09-21) 123.77%
5 years (2016-09-22) 289.33%

Is Zoetis under- or over-valued?

Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zoetis's P/E ratio

Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Zoetis stocks trade at around 50x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.

Zoetis's PEG ratio

Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9087. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Zoetis's EBITDA

Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.1 billion.

The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.

Zoetis financials

Revenue TTM USD$7.4 billion
Operating margin TTM 36.21%
Gross profit TTM USD$4.6 billion
Return on assets TTM 12.36%
Return on equity TTM 51.94%
Profit margin 25.76%
Book value $9.173
Market capitalisation USD$94.3 billion

TTM: trailing 12 months

How to short and sell Zoetis stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ZTS.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.0 million Zoetis stocks held short by investors – that's known as Zoetis's "short interest". This figure is 1.2% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Zoetis stocks can be evaluated.

Zoetis's "short interest ratio" (SIR)

Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis stocks currently shorted divided by the average quantity of Zoetis stocks traded daily (recently around 1.3 million). Zoetis's SIR currently stands at 2.35. In other words for every 100,000 Zoetis stocks traded daily on the market, roughly 2350 stocks are currently held short.

However Zoetis's short interest can also be evaluated against the total number of Zoetis stocks, or, against the total number of tradable Zoetis stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Zoetis stocks in existence, roughly 10 stocks are currently held short) or 0.0062% of the tradable stocks (for every 100,000 tradable Zoetis stocks, roughly 6 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Zoetis.

Find out more about how you can short Zoetis stock.

Zoetis's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zoetis's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 01/01/2019) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zoetis's environmental score

Environmental score: 2.72/100

Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zoetis's social score

Social score: 13/100

Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zoetis's governance score

Governance score: 8.87/100

Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zoetis's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zoetis Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.6
Total ESG percentile 49.38
Environmental score 2.72
Environmental score percentile 1
Social score 13
Social score percentile 1
Governance score 8.87
Governance score percentile 1
Level of controversy 1

Zoetis stock dividends

21%

Dividend payout ratio: 21.3% of net profits

Recently Zoetis has paid out, on average, around 21.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.49% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $0.9 per share.

While Zoetis's payout ratio might seem low, this can signify that Zoetis is investing more in its future growth.

Zoetis's most recent dividend payout was on 1 September 2021. The latest dividend was paid out to all shareholders who bought their stocks by 20 July 2021 (the "ex-dividend date").

Zoetis stock price volatility

Over the last 12 months, Zoetis's stocks have ranged in value from as little as $141.0212 up to $210.1. A popular way to gauge a stock's volatility is its "beta".

ZTS.US volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.6337. This would suggest that Zoetis's stocks are less volatile than average (for this exchange).

Zoetis overview

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site